Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling

Frontiers in Physiology

Volumn 6, Issue OCT, 2015, Pages

  Silva, Marcondes A B ^a   Bruder Nascimento, Thiago ^a   Cau, Stefany B A ^a   Lopes, Rheure A M ^a   Mestriner, Fabiola L A C ^a   Fais, Rafael S ^a   Touyz, Rhian M ^b   Tostes, Rita C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Aldosterone; Mineralocorticoid receptor; Oxidative stress; Type 2 diabetes; Vascular

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALDOSTERONE; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; INSULIN; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; POTASSIUM; REACTIVE OXYGEN METABOLITE; SODIUM; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; POTASSIUM BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASCULAR DISEASE; WESTERN BLOTTING;

EID: 84946561481     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00269     Document Type: Article

References (60)

1. Beltowski, J., Wójcicka, G., and Jamroz-Wisniewska, A. (2006). Role of nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) in the regulation of blood pressure by leptin in lean and obese rats. Life Sci. 79, 63-71. doi: 10.1016/j.lfs.2005.12.041.
2. Brandes, R. P., Schmitz-Winnenthal, F. H., Félétou, M., Gödecke, A., Huang, P. L., Vanhoutte, P. M., et al. (2000). An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc. Natl. Acad. Sci. U.S.A. 97, 9747-9752. doi: 10.1073/pnas.97.17.9747.
3. Briones, A. M., Nguyen Dinh Cat, A., Callera, G. E., Yogi, A., Burger, D., He, Y., et al. (2012). Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59, 1069-1078. doi: 10.1161/HYPERTENSIONAHA.111.190223.
4. Brown, N. J. (2013). Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat. Rev. Nephrol. 9, 459-469. doi: 10.1038/nrneph.2013.110.
5. Bruder-Nascimento, T., Callera, G. E., Montezano, A. C., He, Y., Antunes, T. T., Cat, A. N., et al. (2015). Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: role of Rac1/2-sensitive Nox-dependent pathways. Clin. Sci. (Lond.) 128, 411-423. doi: 10.1042/CS20140456.
6. Bruder-Nascimento, T., da Silva, M. A., and Tostes, R. C. (2014). The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetol. Metab. Syndr. 6:90. doi: 10.1186/1758-5996-6-90.
7. Calhoun, D. A. (2006). Aldosterone and cardiovascular disease: smoke and fire. Circulation 114, 2572-2574. doi: 10.1161/CIRCULATIONAHA.106.668715.
8. Callera, G. E., Touyz, R. M., Tostes, R. C., Yogi, A., He, Y., Malkinson, S., et al. (2005). Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45, 773-779. doi: 10.1161/01.HYP.0000154365.30593.d3.
9. Callera, G. E., Yogi, A., Briones, A. M., Montezano, A. C., He, Y., Tostes, R. C., et al. (2011). Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Cardiovasc. Res. 91, 720-731. doi: 10.1093/cvr/cvr131.
10. Chen, B., Zhao, Q., Ni, R., Tang, F., Shan, L., Cepinskas, I., et al. (2014). Inhibition of calpain reduces oxidative stress and attenuates endothelial dysfunction in diabetes. Cardiovasc. Diabetol. 13:88. doi: 10.1186/1475-2840-13-88.
11. Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., et al. (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31-40. doi: 10.1016/S0140-6736(11)60679-X.
12. Ding, H., Kubes, P., and Triggle, C. (2000). Potassium-and acetylcholine-induced vasorelaxation in mice lacking endothelial nitric oxide synthase. Br. J. Pharmacol. 129, 1194-1200. doi: 10.1038/sj.bjp.0703144.
13. Epstein, M., and Calhoun, D. A. (2011). Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J. Clin. Hypertens. (Greenwich). 13, 644-648. doi: 10.1111/j.1751-7176.2011.00511.x.
14. Farquharson, C. A., and Struthers, A. D. (2000). Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101, 594-597. doi: 10.1161/01.CIR.101.6.594.
15. Fels, J., Oberleithner, H., and Kusche-Vihrog, K. (2010). Menage a trois: aldosterone, sodium and nitric oxide in vascular endothelium. Biochim. Biophys. Acta 1802, 1193-1202. doi: 10.1016/j.bbadis.2010.03.006.
16. Förstermann, U., Closs, E. I., Pollock, J. S., Nakane, M., Schwarz, P., Gath, I., et al. (1994). Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 23, 1121-1131. doi: 10.1161/01.HYP.23.6.1121.
17. Förstermann, U., and Münzel, T. (2006). Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113, 1708-1714. doi: 10.1161/CIRCULATIONAHA.105.602532.
18. Garg, R., Rao, A. D., Baimas-George, M., Hurwitz, S., Foster, C., Shah, R. V., et al. (2015). Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 64, 236-242. doi: 10.2337/db14-0670.
19. Gladwin, M. T. (2006). Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J. Clin. Invest. 116, 2330-2332. doi: 10.1172/JCI29807.
20. Global Burden of Metabolic Risk Factors for Chronic Diseases, C. (2014). Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2, 634-647. doi: 10.1016/S2213-8587(14)70102-0.
21. Hakim, T. S., Sugimori, K., Camporesi, E. M., and Anderson, G. (1996). Half-life of nitric oxide in aqueous solutions with and without haemoglobin. Physiol. Meas. 17, 267-277. doi: 10.1088/0967-3334/17/4/004.
22. Heitzer, T., Krohn, K., Albers, S., and Meinertz, T. (2000). Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 43, 1435-1438. doi: 10.1007/s001250051551.
23. Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., et al. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88, E14-E22. doi: 10.1161/01.RES.88.2.e14.
24. Hollenberg, N. K., Stevanovic, R., Agarwal, A., Lansang, M. C., Price, D. A., Laffel, L. M., et al. (2004). Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int. 65, 1435-1439. doi: 10.1111/j.1523-1755.2004.00524.x.
25. Huang, A., Sun, D., Smith, C. J., Connetta, J. A., Shesely, E. G., Koller, A., et al. (2000). In eNOS knockout mice skeletal muscle arteriolar dilation to acetylcholine is mediated by EDHF. Am. J. Physiol. Heart Circ. Physiol. 278, H762-H768.
26. Krummen, S., Falck, J. R., and Thorin, E. (2005). Two distinct pathways account for EDHF-dependent dilatation in the gracilis artery of dyslipidaemic hApoB+/+mice. Br. J. Pharmacol. 145, 264-270. doi: 10.1038/sj.bjp.0706194.
27. Labuzek, K., Liber, S., Buldak, L., Krupej-Kedzierska, J., Machnik, G., Bobrzyk, M., et al. (2014). Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers. Eur. J. Pharmacol. 726, 96-108. doi: 10.1016/j.ejphar.2014.01.043.
28. Lau, Y. S., Tian, X. Y., Mustafa, M. R., Murugan, D., Liu, J., Zhang, Y., et al. (2013). Boldine improves endothelial function in diabetic db/db mice through inhibition of angiotensin II-mediated BMP4-oxidative stress cascade. Br. J. Pharmacol. 170, 1190-1198. doi: 10.1111/bph.12350.
29. Liu, Y., Li, D., Zhang, Y., Sun, R., and Xia, M. (2014). Anthocyanin increases adiponectin secretion and protects against diabetes-related endothelial dysfunction. Am. J. Physiol. Endocrinol. Metab. 306, E975-E988. doi: 10.1152/ajpendo.00699.2013.
30. Malinski, T., Taha, Z., Grunfeld, S., Patton, S., Kapturczak, M., and Tomboulian, P. (1993). Diffusion of nitric oxide in the aorta wall monitored in situ by porphyrinic microsensors. Biochem. Biophys. Res. Commun. 193, 1076-1082. doi: 10.1006/bbrc.1993.1735.
31. Manrique, C., Lastra, G., and Sowers, J. R. (2014). New insights into insulin action and resistance in the vasculature. Ann. N. Y. Acad. Sci. 1311, 138-150. doi: 10.1111/nyas.12395.
32. Mejía-Vilet, J. M., Ramírez, V., Cruz, C., Uribe, N., Gamba, G., and Bobadilla, N. A. (2007). Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am. J. Physiol. Renal Physiol. 293, F78-F86. doi: 10.1152/ajprenal.00077.2007.
33. Michea, L., Delpiano, A. M., Hitschfeld, C., Lobos, L., Lavandero, S., and Marusic, E. T. (2005). Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146, 973-980. doi: 10.1210/en.2004-1130.
34. Nagata, D., Takahashi, M., Sawai, K., Tagami, T., Usui, T., Shimatsu, A., et al. (2006). Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48, 165-171. doi: 10.1161/01.HYP.0000226054.53527.bb.
35. Nguyen Dinh Cat, A., and Jaisser, F. (2012). Extrarenal effects of aldosterone. Curr. Opin. Nephrol. Hypertens. 21, 147-156. doi: 10.1097/MNH.0b013e32834fb25b.
36. Nietlispach, F., Julius, B., Schindler, R., Bernheim, A., Binkert, C., Kiowski, W., et al. (2007). Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 50, 82-88. doi: 10.1161/HYPERTENSIONAHA.107.088955.
37. Oberleithner, H., Callies, C., Kusche-Vihrog, K., Schillers, H., Shahin, V., Riethmüller, C., et al. (2009). Potassium softens vascular endothelium and increases nitric oxide release. Proc. Natl. Acad. Sci. U.S.A. 106, 2829-2834. doi: 10.1073/pnas.0813069106.
38. Onozato, M. L., Tojo, A., Kobayashi, N., Goto, A., Matsuoka, H., and Fujita, T. (2007). Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol. Dial. Transplant 22, 1314-1322. doi: 10.1093/ndt/gfl780.
39. Pannirselvam, M., Ding, H., Anderson, T. J., and Triggle, C. R. (2006). Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice. Eur. J. Pharmacol. 551, 98-107. doi: 10.1016/j.ejphar.2006.08.086.
40. Patel, B. M., and Mehta, A. A. (2012). Aldosterone and angiotensin: role in diabetes and cardiovascular diseases. Eur. J. Pharmacol. 697, 1-12. doi: 10.1016/j.ejphar.2012.09.034.
41. Pieper, G. M. (1997). Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J. Cardiovasc. Pharmacol. 29, 8-15. doi: 10.1097/00005344-199701000-00002.
42. Resch, M., Schmid, P., Amann, K., Fredersdorf, S., Weil, J., Schach, C., et al. (2011). Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report. Cardiovasc. Diabetol. 10:94. doi: 10.1186/1475-2840-10-94.
43. Romagni, P., Rossi, F., Guerrini, L., Quirini, C., and Santiemma, V. (2003). Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166, 345-349. doi: 10.1016/S0021-9150(02)00363-5.
44. Ronconi, V., Turchi, F., Appolloni, G., Di Tizio, V., Boscaro, M., and Giacchetti, G. (2012). Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr. Vasc. Pharmacol. 10, 238-246. doi: 10.2174/157016112799304969.
45. Schmidt, B. M., Oehmer, S., Delles, C., Bratke, R., Schneider, M. P., Klingbeil, A., et al. (2003). Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 42, 156-160. doi: 10.1161/01.HYP.0000083298.23119.16.
46. Scotland, R. S., Madhani, M., Chauhan, S., Moncada, S., Andresen, J., Nilsson, H., et al. (2005). Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 111, 796-803. doi: 10.1161/01.CIR.0000155238.70797.4E.
47. Sherajee, S. J., Fujita, Y., Rafiq, K., Nakano, D., Mori, H., Masaki, T., et al. (2012). Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler. Thromb. Vasc. Biol. 32, 257-263. doi: 10.1161/ATVBAHA.111.240697.
48. Silva, M. A., Cau, S. B., Lopes, R. A., Manzato, C. P., Neves, K. B., Bruder-Nascimento, T., et al. (2015). Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus. Clin. Sci. (Lond.) 129, 533-545. doi: 10.1042/CS20140758.
49. Stasch, J. P., Pacher, P., and Evgenov, O. V. (2011). Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123, 2263-2273. doi: 10.1161/CIRCULATIONAHA.110.981738.
50. Stasch, J. P., Schmidt, P. M., Nedvetsky, P. I., Nedvetskaya, T. Y., H, S. A., Meurer, S., et al. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 116, 2552-2561. doi: 10.1172/JCI28371.
51. Toda, N., Nakanishi, S., and Tanabe, S. (2013). Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br. J. Pharmacol. 168, 519-533. doi: 10.1111/j.1476-5381.2012.02194.x.
52. Touyz, R. M. (2004). Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz. J. Med. Biol. Res. 37, 1263-1273. doi: 10.1590/S0100-879X2004000800018.
53. Velmurugan, G. V., Sundaresan, N. R., Gupta, M. P., and White, C. (2013). Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc. Res. 100, 143-150. doi: 10.1093/cvr/cvt125.
54. Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R. M., and Schiffrin, E. L. (2002). Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40, 504-510. doi: 10.1161/01.HYP.0000034738.79310.06.
55. Waldron, G. J., Ding, H., Lovren, F., Kubes, P., and Triggle, C. R. (1999). Acetylcholine-induced relaxation of peripheral arteries isolated from mice lacking endothelial nitric oxide synthase. Br. J. Pharmacol. 128, 653-658. doi: 10.1038/sj.bjp.0702858.
56. Wenzel, P., Daiber, A., Oelze, M., Brandt, M., Closs, E., Xu, J., et al. (2008). Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 198, 65-76. doi: 10.1016/j.atherosclerosis.2007.10.003.
57. Wölfle, S. E., and de Wit, C. (2005). Intact endothelium-dependent dilation and conducted responses in resistance vessels of hypercholesterolemic mice in vivo. J. Vasc. Res. 42, 475-482. doi: 10.1159/000088101.
58. Zannad, F. (1995). Aldosterone and heart failure. Eur. Heart J. 16(Suppl. N), 98-102. doi: 10.1093/eurheartj/16.suppl_N.98.
59. Zhang, X., Liu, J., Pang, X., Zhao, J., Wang, S., and Wu, D. (2014). Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-kappaB signal pathway in rat vascular smooth muscle cells. Mol. Cell. Endocrinol. 395, 61-68. doi: 10.1016/j.mce.2014.08.003.
60. Zimmet, P., Alberti, K. G., and Shaw, J. (2001). Global and societal implications of the diabetes epidemic. Nature 414, 782-787. doi: 10.1038/414782a.